Sugi Predict

Sugi Predict / Compounds / SCHEMBL1726536

SCHEMBL1726536

SCHEMBL1726536

CCCCCCCCOP(OC)OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 9/20 0.41
▸ CA2 P00918 9/20 0.41
▸ CA9 Q16790 8/20 0.41
▸ CA12 O43570 3/20 0.41
▸ CA7 P43166 3/20 0.41
▸ CA14 Q9ULX7 3/20 0.41
▸ CA3 P07451 2/20 0.41
▸ CA4 P22748 2/20 0.41
▸ CA6 P23280 2/20 0.41
▸ CA5A P35218 2/20 0.41
▸ CA5B Q9Y2D0 2/20 0.41
▸ TSHR P16473 2/20 0.40
▸ RECQL P46063 2/20 0.40
▸ THRB P10828 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607428 1.00 CA1 (0.41) CA1CA2CA9CA12CA7
SCHEMBL1727012 1.00 CA1 (0.41) CA1CA2CA9CA12CA7
SCHEMBL1726541 1.00 CA1 (0.41) CA1CA2CA9CA12CA7
SCHEMBL11069711 1.00 CA1 (0.41) CA1CA2CA9CA12CA7
SCHEMBL1725075 1.00 CA1 (0.41) CA1CA2CA9CA12CA7
Hydrochloric Acid SCHEMBL31521730 0.98 CA1 (0.40) CA1CA2CA9CA12CA7
Hydrochloric Acid SCHEMBL31521729 0.98 CA1 (0.40) CA1CA2CA9CA12CA7
SCHEMBL1725290 0.97 CA1 (0.39) CA1CA2CA9CA12CA7
SCHEMBL1726487 0.95 CA1 (0.41) CA1CA2CA9CA12CA7
SCHEMBL11437081 0.95 CA1 (0.41) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002313-A1 [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2024-01-04 — — US disclosed
CN-117098749-A [11C] Labeled acyclic retinoids, central nervous system activators and methods for their manufacture 国立研究开发法人国立长寿医疗研究中心 2023-11-21 — — CN disclosed
EP-4249058-A1 [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME National Center for Geriatrics and Gerontology (JP) 2023-09-27 — — EP disclosed
EP-3144064-B1 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME CHEVRON PHILLIPS CHEMICAL CO LP (US) 2021-07-28 — — EP disclosed
EP-3377596-A1 SELECTIVE HYDROGENATION USING A FLOW INDEX Chevron Phillips Chemical Company LP (US) 2018-09-26 — — EP disclosed
CN-108291157-A Selective hydrogenation using flow index 切弗朗菲利浦化学公司 2018-07-17 — — CN disclosed
US-20180148260-A1 Selective Hydrogenation Using a Flow Index CHEVRON PHILLIPS CHEMICAL COMPANY LP 2018-05-31 — — US disclosed
US-9914676-B2 Selective hydrogenation using a flow index CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2018-03-13 — — US disclosed
US-20170349507-A1 Selective Hydrogenation Using a Flow Index CHEVRON PHILLIPS CHEMICAL COMPANY LP 2017-12-07 — — US disclosed
EP-3218104-A1 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME Chevron Phillips Chemical Company LP (US) 2017-09-20 — — EP disclosed
US-20150197464-A1 Selective Hydrogenation Catalyst and Methods of Making and Using Same CHEVRON PHILLIPS CHEMICAL COMPANY LP 2015-07-16 — — US disclosed
US-9012348-B2 Selective hydrogenation catalyst and methods of making and using same CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2015-04-21 — — US disclosed
US-20140107383-A1 Selective Hydrogenation Catalyst and Methods of Making and Using Same CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2014-04-17 — — US disclosed
US-8633127-B2 Selective hydrogenation catalyst and methods of making and using same CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2014-01-21 — — US disclosed
CN-102341175-A Selective hydrogenation catalyst and methods of making and using same CHEVRON PHILLIPS CHEMICAL CO 2012-02-01 — — CN disclosed
EP-2403642-A2 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME Chevron Phillips Chemical Company LP (US) 2012-01-11 — — EP disclosed
WO-2010101736-A2 SELECTIVE HYDROGENATION CATALYST AND METHODS OF MAKING AND USING SAME CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2010-09-10 — — WO disclosed
US-20100228065-A1 Selective Hydrogenation Catalyst and Methods of Making and Using Same CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2010-09-09 — — US disclosed
US-5600034-A HEAT TREATING DIALLYL ETHERS IN PRESENCE OF CATALYST CONTAINING PALLADIUM AND PHOSPHORUS COMPOUNDS MITSUBISHI CHEMICAL CORPORATION (JP) 1997-02-04 — — US disclosed
US-5583271-A Method for continuously producing alkadienols MITSUBISHI CHEMICAL CORPORATION (JP) 1996-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002313-A1 [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME NR2E3, FABP7, RARB CA1 355/4885CA2 2385/4885CA9 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.